CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally
April 28 2022 - 6:30AM
Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential
biodata life science partner for rare and neurodegenerative
diseases, today announced it has extended its partnership with
Takeda (TSE: 4502/NYSE: TAK) to diagnose patients with rare
metabolic and rare neurodegenerative diseases.
Under the agreement, CENTOGENE will continue providing Takeda
access to diagnostic testing for patients around the world. The
commercial fee-for-service agreement focuses on expanding patient
access to diagnostics for lysosomal storage disorders such as Fabry
and Gaucher diseases, and Hunter syndrome.
“We are excited to extend our partnership with Takeda to provide
diagnostics and accelerate improved treatment and health outcomes
for patients globally,” said Kim Stratton, CEO of CENTOGENE. “With
our highly differentiated diagnostic services, CENTOGENE’s network
of over 29,000 physicians, and the CENTOGENE Biodatabank driving
novel insights, we are uniquely positioned to add significant value
to biopharma partners along their entire development pipeline. This
collaboration will support the expansion of Takeda’s world-class
enzyme replacement treatments and most importantly, bring real
solutions to under-served patient communities.”
Within the partnership, CENTOGENE’s proprietary CentoCard® dried
blood spot solution provides easy logistics for central diagnostic
testing. A key asset to the partnership is the CENTOGENE
Biodatabank, the world’s largest real-world data repository for
rare and neurodegenerative diseases, which is pioneering access to
commercial multiomic products on the market today.
In January 2015, CENTOGENE originally entered into an agreement
with Shire Pharmaceuticals, which was acquired in 2019 by Takeda,
to provide diagnostic testing capability to enhance early diagnosis
of patients suffering from genetic rare diseases. Last year, the
contract was extended until March 2022.
About CENTOGENE
CENTOGENE engages in diagnosis and research around rare diseases
transforming real-world clinical, genetic, and multiomic data to
diagnose, understand, and treat rare diseases. Our goal is to bring
rationality to treatment decisions and to accelerate the
development of new orphan drugs by using our extensive rare disease
knowledge and data. CENTOGENE has developed a global proprietary
rare disease platform based on our real-world data repository of
over 650,000 individuals representing over 120 different
countries.
The Company’s platform includes epidemiologic, phenotypic, and
genetic data that reflects a global population, as well as a
biobank of patients’ blood samples and cell cultures. CENTOGENE
believes this represents the only platform focused on comprehensive
analysis of multi-level data to improve the understanding of rare
hereditary diseases. It allows for better identification and
stratification of patients and their underlying diseases to enable
and accelerate discovery, development, and access to orphan drugs.
As of December 31, 2021, the Company collaborated with over 30
pharmaceutical partners.
For more information, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others,
negative economic and geopolitical conditions and instability and
volatility in the worldwide financial markets, possible changes in
current and proposed legislation, regulations and governmental
policies, pressures from increasing competition and consolidation
in our industry, the expense and uncertainty of regulatory
approval, including from the U.S. Food and Drug Administration, our
reliance on third parties and collaboration partners, including our
ability to manage growth and enter into new client relationships,
our dependency on the rare disease industry, our ability to manage
international expansion, our reliance on key personnel, our
reliance on intellectual property protection, fluctuations of our
operating results due to the effect of exchange rates, our ability
to streamline cash usage, our requirement for additional financing,
or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on March 30, 2022,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Media Contact:
CENTOGENE Lennart
Streibel Investor
Relations Investor.Relations@centogene.com
Ben Legg Corporate Communications Press@centogene.com
Stern IR Brendan Payne+1 (212)
698 8695brendan.payne@sternir.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Sep 2023 to Sep 2024